Hyperglycemia and the Extra-pancreatic Effect of Incretins

Rigshospitalet

Status: Completed

Conditions: Extra-pancreatic Incretin Effect; Glucose Effectiveness

Treatments: Biological: GLP-1; Biological: Saline; Biological: GIP

Study type: Interventional

Funder types: Other

Identifiers

NCT01749163

PancClamp

Details and patient eligibility

About

Incretin hormones (GLP-1 and GIP) released from the intestine in response to meal ingestion augment insulin secretion from the pancreas to help maintain glycemic control. Studies in vitro and in vivo have shown that these incretin hormones also have functional effects in other tissues independent of the insulin secretory response. Both GLP-1 and GIP stimulate insulin secretion in a glucose-dependent manner, however the glucose-dependency of their extra-pancreatic effects has not been examined in vivo. By using pancreatic clamp methodology during euglycemic and hyperglycemic conditions we will test the hypothesis that extra-pancreatic effects of GLP-1 and GIP are glucose-dependent.

Enrollment: 20 patients

Sex: Male

Ages: 18 to 60 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• age 18-60 years
• BMI 18-30 kg/m2
• Male
• Normal glycemic control (fasting glucose <5.6 mM)

Exclusion criteria

• Evidence of chronic disease
• Smoking
• Active weight loss (>2 kg in previous 6 months)
• Treatment with drugs known to affect our outcome varaibles

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)

---

20 participants in 3 patient groups

Control

Experimental group

Description:

Saline will be coninfused during the pancreatic clamp

Treatment:

Biological: Saline

GIP

Experimental group

Description:

GIP will be infused intravenously during the pancreatic clamp at 1.5 pmol/kg/min

Treatment:

Biological: GIP

GLP-1

Experimental group

Description:

GLP-1 will be infused intravenously during the pancreatic clamp at 0.5 pmol/kg/min

Treatment:

Biological: GLP-1